Glycopyrrolate Oral
Active ingredient: Glycopyrrolate
In short: Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).
What is Glycopyrrolate Oral used for?
Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).
Glycopyrrolate Oral dosage
Glycopyrrolate oral solution must be measured and administered with an accurate measuring device .
Initiate dosing at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5 to 7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5 to 3 mg per dose based upon weight. For greater detail, see Table 1.
During the four-week titration period, dosing can be increased with the recommended dose titration schedule while ensuring that the anticholinergic adverse events are tolerable. Prior to each increase in dose, review the tolerability of the current dose level with the patient's caregiver.
Glycopyrrolate oral solution should be dosed at least one hour before or two hours after meals.
The presence of high fat food reduces the oral bioavailability of Glycopyrrolate oral solution if taken shortly after a meal .
Table 1: Recommended Dose Titration Schedule (each dose to be given three times daily)
Weight | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Dose Level 5
kg | lbs | (⁓0.02 mg/kg) | (⁓0.04 mg/kg) | (⁓0.06 mg/kg) | (⁓0.08 mg/kg) | (⁓0.1 mg/kg)
13-17 | 27-38 | 0.3 mg | 1.5 mL | 0.6 mg | 3 mL | 0.9 mg | 4.5 mL | 1.2 mg | 6 mL | 1.5 mg | 7.5 mL
18-22 | 39-49 | 0.4 mg | 2 mL | 0.8 mg | 4 mL | 1.2 mg | 6 mL | 1.6 mg | 8 mL | 2 mg | 10 mL
23-27 | 50-60 | 0.5 mg | 2.5 mL | 1 mg | 5 mL | 1.5mg | 7.5 mL | 2 mg | 10mL | 2.5 mg | 12.5mL
28-32 | 61-71 | 0.6 mg | 3 mL | 1.2 mg | 6 mL | 1.8 mg | 9 mL | 2.4 mg | 12 mL | 3 mg | 15 mL
33-37 | 72-82 | 0.7 mg | 3.5 mL | 1.4 mg | 7 mL | 2.1 mg | 10.5 mL | 2.8 mg | 14 mL | 3 mg | 15 mL
38-42 | 83-93 | 0.8 mg | 4 mL | 1.6 mg | 8 mL | 2.4 mg | 12 mL | 3 mg | 15 mL | 3 mg | 15 mL
43-47 | 94-104 | 0.9 mg | 4.5 mL | 1.8 mg | 9 mL | 2.7 mg | 13.5 mL | 3 mg | 15 mL | 3 mg | 15 mL
≥48 | ≥105 | 1 mg | 5 mL | 2 mg | 10 mL | 3 mg | 15 mL | 3 mg | 15 mL | 3 mg | 15 mL
How to take Glycopyrrolate Oral — instructions & advice from the label
See FDA-approved patient labeling (Patient Information)
Advise patients/caregivers to measure Glycopyrrolate oral solution with an accurate measuring device. A household teaspoon is not an accurate measuring device. Patients/caregivers should use a dosing cup available in pharmacies to accurately measure the correct milliliter dose. An oral syringe, also available in pharmacies, should be used to dispense Glycopyrrolate oral solution into the child's mouth from the cup. A pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.
Administering Glycopyrrolate oral solution with a high fat meal substantially reduces the amount of glycopyrrolate absorbed. Administer Glycopyrrolate oral solution at least one hour before or two hours after meals.
Glycopyrrolate oral solution is started at a low dose and gradually titrated over a period of weeks based on therapeutic response and adverse reactions. Patients/caregivers should not increase the dose without the physician's permission. …
Warnings & precautions
Do not take this medicine if: Glycopyrrolate oral solution is contraindicated in:
Patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralyticileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis).
Patients taking solid oral dosage forms of potassium chloride. The passage of potassium chloride tablets through the gastrointestinal (GI) tract may be arrested or delayed with coadministration of Glycopyrrolate oral solution.
Constipation is a common dose-limiting adverse reaction which sometimes leads to glycopyrrolate discontinuation . Assess patients for constipation, particularly within 4 to 5 days of initial dosing or after a dose increase. Intestinal pseudo-obstruction has been reported and may present as abdominal distention, pain, nausea or vomiting.
Diarrhea may be an early symptom of incomplete mechanical intestinal obstruction, especially in patients with ileostomy or colostomy. If incomplete mechanical intestinal obstruction is suspected, discontinue treatment with Glycopyrrolate oral solution and evaluate for intestinal obstruction.
In the presence of high ambient temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as Glycopyrrolate oral solution. Advise patients/ caregivers to avoid exposure of the patient to hot or very warm environmental temperatures.
Glycopyrrolate oral solution may produce drowsiness or blurred vision. As appropriate for a given age, warn the patient not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking Glycopyrrolate oral solution. …
Glycopyrrolate Oral side effects
The following serious adverse reactions are described elsewhere in the labeling:
Constipation or intestinal pseudo-obstruction
Incomplete mechanical intestinal obstruction
The most common adverse reactions reported with Glycopyrrolate oral solution are dry mouth, vomiting, constipation, flushing, and nasal congestion.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Glycopyrrolate oral solution in 151 subjects, including 20 subjects who participated in an 8-week placebo-controlled study (Study 1) and 137 subjects who participated in a 24-week open-label study (six subjects who received Glycopyrrolate oral solution in the placebo-controlled study and 131 new subjects).
Table 2 presents adverse reactions reported by ≥ 15% of Glycopyrrolate oral solution-treated subjects from the placebo controlled clinical trial. …
Drug interactions
Drugs Affected by Reduced GI Transit Time
Glycopyrrolate reduces GI transit time, which may result in altered release of certain drugs when formulated in delayed- or controlled-release dosage forms.
The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated .
Digoxin administered as slow dissolution oral tablets may have increased serum levels and enhanced action when administered with glycopyrrolate. Monitor patients receiving slow dissolution digoxin for increased action if glycopyrrolate is coadministered regularly. Consider the use of other oral dosage forms of digoxin (e.g., elixir or capsules).
Amantadine
The anticholinergic effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during coadministration of amantadine.
Drugs Whose Plasma Levels May be Increased by Glycopyrrolate
Coadministration of glycopyrrolate may result in increased levels of certain drugs.
Atenolol's bioavailability may be increased with coadministration of glycopyrrolate. A reduction in the atenolol dose may be needed. …
About this medicine
Glycopyrrolate oral solution is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is:
The empirical formula for Glycopyrrolate oral solution is C
19H
28BrNO
3 and the molecular weight is 398.33. The inactive ingredients in Glycopyrrolate oral solution are: citric acid anhydrous, natural and artificial cherry flavor, glycerin, methylparaben, propylene glycol, propylparaben, sodium saccharin, sorbitol, trisodium citrate and purified water.
How it works: Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors. Glycopyrrolate inhibits the action of acetylcholine on salivary glands thereby reducing the extent of salivation.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0f05c5d3-9c41-4dae-88d1-18cbddc69487. Read the full official label on DailyMed.